Tags : Complicated Intra-Abdominal Bacterial Infections

Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated

Shots: The US FDA approval is based on clinical safety and efficacy data of Recarbrio (injection, 1.25gm) approved for cUTI including pyelonephritis, caused by certain Gram-negative microorganism and also indicated for patients with cIAI aged 18yrs.+ who have limited or no alternative treatment options The US FDA reviewed its NDA under Qualified Infectious Disease Product […]Read More